Drug design of Src Kinase inhibitor: An overview

Abstract

Drug discovery for chemotherapeutic agent is making an extraordinary progress in the realm of advancing novel oncogenic protein kinase inhibitor lead compounds of varying chemical structure and biological mechanism. In the last 40 years, the first protein kinase, pp60src(Src), was discovered as a prototype of the new current superfamily of Ser/Thr, Tyr and dual-specificity protein kinases. In this review, we will highlight Src kinase inhibitors with respect to the structural biology, drug design, chemical diversity, and biological properties. This will help medicinal chemist to the design of more potent Src kinase inhibitors for resistive target protein in cancer